Log in to search using one of your social media accounts:

 

What Are the Side Effects of Strattera?
Title: What Are the Side Effects of Strattera?Category: Doctor's& Expert's views on SymptomsCreated: 6/8/2017 12:00:00 AMLast Editorial Review: 6/8/2017 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - June 8, 2017 Category: Pediatrics Source Type: news

D.C. Week: FDA Okays Generic Stattera, Insurance Stabilization Urged
(MedPage Today) -- FDA approves the first generic version of atomoxetine for treating ADHD (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 3, 2017 Category: American Health Source Type: news

FDA Approves Generic Atomoxetine for ADHD (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM The FDA has approved the first generic version … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 1, 2017 Category: Primary Care Source Type: news

Health Highlights: May 31, 2017
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Generic ADHD Drugs Approved by FDA The first generic versions of the attention-deficit/hyperactivity disorder (ADHD) drug Strattera (atomoxetine)... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 31, 2017 Category: General Medicine Source Type: news

FDA approves first generic Strattera for the treatment of ADHD
The U.S. Food and Drug Administration has approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma Limited and Glenmark Pharmaceuticals Limited gained approval to market atomoxetine in multiple strengths. (Source: World Pharma News)
Source: World Pharma News - May 31, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Clears First Generic Versions of Strattera for ADHD FDA Clears First Generic Versions of Strattera for ADHD
Generic versions of atomoxetine for the treatment of ADHD in adults and children will be available in multiple strengths.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 30, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

ADHD: FDA OKs Strattera Generic
(MedPage Today) -- Four companies get green light to market (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - May 30, 2017 Category: Neurology Source Type: news

FDA approves first generic Strattera for the treatment of ADHD
The U.S. Food and Drug Administration today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 30, 2017 Category: American Health Source Type: news

FDA Approves First Generic Strattera for the Treatment of ADHD
May 30, 2017 -- The U.S. Food and Drug Administration today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. Apotex Inc., Teva Pharmaceuticals... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 30, 2017 Category: Pharmaceuticals Source Type: news

Vyvanse vs. Strattera
Title: Vyvanse vs. StratteraCategory: MedicationsCreated: 2/23/2017 12:00:00 AMLast Editorial Review: 2/23/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - February 23, 2017 Category: Drugs & Pharmacology Source Type: news

Atomoxetine vs. Adderall
Title: Atomoxetine vs. AdderallCategory: MedicationsCreated: 1/27/2017 12:00:00 AMLast Editorial Review: 1/27/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - January 27, 2017 Category: Drugs & Pharmacology Source Type: news

Strattera (Atomoxetine HCl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 12, 2016 Category: Drugs & Pharmacology Source Type: news

Strattera (atomoxetine)
Title: Strattera (atomoxetine)Category: MedicationsCreated: 1/22/2003 12:00:00 AMLast Editorial Review: 9/9/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - September 9, 2016 Category: Drugs & Pharmacology Source Type: news

Atomoxetine improves critical reading skills in children with dyslexia
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study shows significant improvement in critical components of reading, including decoding and vocabulary, among children treated with atomoxetine compared to placebo. Atomoxetine treatment was also associated with significant reductions in symptoms of attention-deficit/hyperactivity disorder (ADHD) in children with both dyslexia and ADHD or ADHD alone, as reported in the study published in Journal of Child and Adolescent Psychopharmacology. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 7, 2016 Category: Global & Universal Source Type: news

Risk of suicidal events with atomoxetine compared to stimulant treatment: a cohort study - Linden S, Bussing R, Kubilis P, Gerhard T, Segal R, Shuster JJ, Winterstein AG.
BACKGROUND: Antidepressant effects on increased suicidality in children have raised public concern in recent years. Approved in 2002 for attention-deficit/hyperactivity disorder treatment, the selective noradrenalin-reuptake-inhibitor atomoxetine was initi... (Source: SafetyLit)
Source: SafetyLit - June 4, 2016 Category: Global & Universal Tags: Age: Adolescents Source Type: news

No increased suicide risk from atomoxetine in youths with ADHD
Youths who take atomoxetine for attention-deficit/hyperactivity disorder or other mental health conditions do not appear any more likely to attempt or complete suicide than those treated with... (Source: Pediatric News)
Source: Pediatric News - April 26, 2016 Category: Journals (General) Source Type: news

No increased suicide risk from atomoxetine in youths with ADHD
Youths who take atomoxetine for attention-deficit/hyperactivity disorder or other mental health conditions do not appear any more likely to attempt or complete suicide than those treated with... (Source: Family Practice News)
Source: Family Practice News - April 26, 2016 Category: Primary Care Source Type: news

Solving the Puzzle of Your ADD/ADHD Child: Natural Alternatives for Hard-to-Raise Children
Raising any child can feel like a puzzle. However, when your child has ADD or ADHD, that puzzle can seem to have a few missing pieces. This was the case for Laura J. Stevens with her first son, Tommy. As she describes in Solving the Puzzle of Your ADD/ADHD Child: Natural Alternatives for Hard-to-Raise Children, when Tommy was four, a pediatric neurologist concluded that he was hyperactive and “would probably experience sever learning problems in school and always require special education classes.” Something about that conclusion didn’t sit well with Stevens, who has a master’s degree in n...
Source: Psych Central - February 13, 2016 Category: Psychiatry Authors: Claire Nana Tags: Attention Deficit Disorder Book Reviews Children and Teens Diet & Nutrition General Healthy Living School Issues adhd food adhd home remedies adhd natural remedies bad food for add books on add books on adhd books on children wit Source Type: news

Differences in abuse potential of ADHD drugs measured by contrasting poison centre and therapeutic use data - Jensen LS, Pagsberg AK, Dalhoff KP.
Context. Atomoxetine (ATX) is the treatment of choice for attention deficit hyperactivity disorders with co-morbid risk of drug abuse, although its abuse potential needs to be qualified. The purpose of this study is to analyse ATX misuse in relation to the... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - November 21, 2015 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

Attention deficit hyperactivity disorder medication use among teens and young adults - Johansen ME, Matic K, McAlearney AS.
PURPOSE: The purpose of this study was to determine rates of stimulant/atomoxetine use among teens (aged 12-17 years) and young adults (aged 18-23 years) and to investigate associations in medication use before and after the transition from teen to young a... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - June 5, 2015 Category: Global & Universal Tags: Age: Adolescents Source Type: news

The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine - Pringsheim T, Hirsch L, Gardner D, Gorman DA.
OBJECTIVE: Children with attention-deficit hyperactivity disorder (ADHD) may have oppositional behaviour, conduct problems, and aggression. These symptoms vary in severity, and may be related to a comorbid diagnosis of oppositional defiant disorder (ODD) o... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - April 24, 2015 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Efficacy of atomoxetine for symptoms of attention-deficit/hyperactivity disorder in children with a history of child abuse - Sugimoto A, Suzuki Y, Endo T, Matsumoto K, Sugiyama T, Someya T.
OBJECTIVE: Recent studies suggest that the severity and drug response of depression and anxiety are correlated with childhood abuse. However, whether a history of child abuse can predict the severity and/or drug response of attention-deficit/hyperactivity ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - April 23, 2015 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine - Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK.
OBJECTIVE: This meta-analysis examined suicide-related events in the acute phases of double-blind, placebo-controlled atomoxetine trials in pediatric and adult patients with attention-deficit/hyperactivity disorder (ADHD). METHODS: A total of 3883 ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - July 17, 2014 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Painful Priapism, ADHD Drugs, and other News of Tox on the Web
This article is essential reading. (For more on tramadol, click here.) [HT @DavidJuurlink] Carbon Monoxide Toxicity: Over at Academic Life in Emergency Medicine, there is an excellent review of carbon monoxide toxicity by Dr. Dan Repplinger, with expert peer review by Dr. David Juurlink. The review focuses on the indications for hyberbaric oxygen therapy. Dr. Juurlink summation reflects my opinion on the matter exactly: ” . . .there are no absolute indications for HBO on patients with CO poisoning. Don’t let anyone tell you otherwise.” Another must-read. Liver toxicity and dietary supplemen...
Source: The Poison Review - December 24, 2013 Category: Toxicology Authors: Leon Tags: Medical ADHD atomoxetine attention deficit hyperactivity disorder carbon monoxide poisoning cyanide deborah blum dietary supplements hepatotoxicity hyperbaric oxygen lead toxicity liver injury strattera tox on the web tramadol Source Type: news

Must-read: The NY Times on the marketing of ADHD drugs
This article, although it really doesn’t feature a smoking gun, is important reading. Highly recommended.     (Source: The Poison Review)
Source: The Poison Review - December 16, 2013 Category: Toxicology Authors: Leon Tags: Medical adderall ADHD attention deficit hyperactivity disorder concerta intuniv marketing new york times Ritalin Source Type: news

Drug May Improve Driving Skills in Adults With ADHDDrug May Improve Driving Skills in Adults With ADHD
The ADHD medication atomoxetine may improve the driving performance of adult patients with the disorder, according to the first "on-the-road" driving study to evaluate these issues. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 9, 2013 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Safety of non-therapeutic atomoxetine exposures-a national poison data system study - Monte AA, Ceschi A, Bodmer M.
This study's objective is to assess the safety of non-therapeutic atomoxetine exposures reported to the US National Poison Database System (NPDS). METHODS: This is a retrospective database study of non-therapeutic single agent ingestions of atomoxeti... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - August 1, 2013 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

DSM-5 likely to increase cases of ADHD drug overdose
3.5 out of 5 stars Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of toxicity, and Management. Spiller HA et al. CNS Drugs 2013 Jun 12 [Epub ahead of print] Abstract There is a very good chance that in the near future we will see an increasing number of cases involving ingestion or overdose of drugs used to treat Attention-Deficit Hyperactivity Disorder (ADHD). DSM-5, released last month, has changed criteria for making a diagnosis of ADHD that will radically expand the the population of both children and adults who could be labelled with the condition and be candidat...
Source: The Poison Review - July 3, 2013 Category: Toxicology Authors: Leon Tags: Medical adderall ADHD atomoxetine attention deficit hyperactivity disorder clonidcine DSM guanfacine modafinil psychostimulant. methylphenidate Source Type: news

Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials - Bushe CJ, Savill NC.
BACKGROUND: Attention Deficit Hyperactivity Disorder (ADHD) is becoming an increasingly commonly diagnosed and treated childhood illness. Untreated ADHD is recognised as an independent risk factor for suicide-related events and deliberate self-harm and is ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - June 26, 2013 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Lisdexamfetamine Dimesylate Demonstrates Significantly Faster Response, Greater Reductions Of Core ADHD Symptoms Than Atomoxetine In Study
Shire plc (LSE: SHP, NASDAQ: SHPG) presents scientific data comparing the efficacy and safety of the Attention Deficit/Hyperactivity Disorder (ADHD) treatments lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) at the 4th World Congress on ADHD, Milan, Italy. The study (SPD489-317) is the first head-to-head trial in children and adolescents with at least moderately symptomatic ADHD and an inadequate response to previous methylphenidate therapy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 11, 2013 Category: Consumer Health News Tags: ADHD Source Type: news